Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Body mass index
Epidemiology
Lean NAFLD
Meta-analysis
Metabolism
Non-overweight
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
20
04
2020
revised:
28
05
2020
accepted:
17
06
2020
pubmed:
24
6
2020
medline:
31
7
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
Lean non-alcoholic fatty liver disease (NAFLD) is a potentially metabolically unhealthy state that refers to NAFLD occurring in non-overweight/nonobese subjects. Yet its global epidemiology and metabolic characteristics are not extensively elucidated. PubMed, EMBASE, Web of Science and Cochrane databases were searched for eligible studies until January 2020. Random-effects/fixed-effects models were used to estimate the global prevalence of lean NAFLD and to compare clinical characteristics among lean non-NAFLD, lean NAFLD, and overweight/obese NAFLD subjects. "Lean" NAFLD was defined by ethnic-specific body mass index measurements in the normal range. Meta-regression and subgroup analyses were performed to determine potential sources of heterogeneity. A total of 33 observational studies were included with 205 307 individuals from 14 countries. The global prevalence of lean NAFLD was 4.1% (95% confidence interval [CI]: 3.4-4.8%). In lean subjects, the prevalence of NAFLD was 9.7% (95% CI: 7.7-11.8%). The prevalence of lean NAFLD with diabetes, hypertension, metabolic syndrome, dyslipidemia, or central obesity was 0.6% (95% CI: 0.4-0.9%), 1.8% (95% CI: 1.2-2.5%), 1.4% (95% CI: 1.0-1.9%), 2.8% (95% CI: 1.9-3.7%), and 2.0% (95% CI: 1.6-2.4%), respectively. The prevalence of lean NAFLD showed an upward trend between 1988 and 2017. Asian individuals had the highest prevalence of lean NAFLD (4.8%, 95% CI: 4.0-5.6%). Middle-aged people (45-59 years old) had the highest prevalence of lean NAFLD (4.4%, 95% CI: 3.2-5.5%). The prevalence of metabolic complications in lean non-NAFLD, lean NAFLD, and overweight/obese NAFLD groups increased sequentially. Lean NAFLD occurs with metabolic complications and is not an uncommon condition. The highest prevalence of lean NAFLD occurs in middle-aged individuals of Asian countries.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Lean non-alcoholic fatty liver disease (NAFLD) is a potentially metabolically unhealthy state that refers to NAFLD occurring in non-overweight/nonobese subjects. Yet its global epidemiology and metabolic characteristics are not extensively elucidated.
METHODS
METHODS
PubMed, EMBASE, Web of Science and Cochrane databases were searched for eligible studies until January 2020. Random-effects/fixed-effects models were used to estimate the global prevalence of lean NAFLD and to compare clinical characteristics among lean non-NAFLD, lean NAFLD, and overweight/obese NAFLD subjects. "Lean" NAFLD was defined by ethnic-specific body mass index measurements in the normal range. Meta-regression and subgroup analyses were performed to determine potential sources of heterogeneity.
RESULTS
RESULTS
A total of 33 observational studies were included with 205 307 individuals from 14 countries. The global prevalence of lean NAFLD was 4.1% (95% confidence interval [CI]: 3.4-4.8%). In lean subjects, the prevalence of NAFLD was 9.7% (95% CI: 7.7-11.8%). The prevalence of lean NAFLD with diabetes, hypertension, metabolic syndrome, dyslipidemia, or central obesity was 0.6% (95% CI: 0.4-0.9%), 1.8% (95% CI: 1.2-2.5%), 1.4% (95% CI: 1.0-1.9%), 2.8% (95% CI: 1.9-3.7%), and 2.0% (95% CI: 1.6-2.4%), respectively. The prevalence of lean NAFLD showed an upward trend between 1988 and 2017. Asian individuals had the highest prevalence of lean NAFLD (4.8%, 95% CI: 4.0-5.6%). Middle-aged people (45-59 years old) had the highest prevalence of lean NAFLD (4.4%, 95% CI: 3.2-5.5%). The prevalence of metabolic complications in lean non-NAFLD, lean NAFLD, and overweight/obese NAFLD groups increased sequentially.
CONCLUSIONS
CONCLUSIONS
Lean NAFLD occurs with metabolic complications and is not an uncommon condition. The highest prevalence of lean NAFLD occurs in middle-aged individuals of Asian countries.
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2041-2050Subventions
Organisme : NIHR Southampton Biomedical Research Centre
ID : IS-BRC-20004
Organisme : University of Verona
Organisme : National Natural Science Foundation of China
ID : 81500665
Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 2020 Apr 8:S0168-8278(20)30201-4. https://doi.org/10.1016/j.jhep.2020.03.039.
Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease. J. Hepatol. 2020; 72: 785-801.
Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metab: Clin Exp 2020: 154170.
Byrne CD, Targher G. NAFLD: a multisystem disease. J. Hepatol. 2015; 62: S47-S64.
Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of nonalcoholic fatty liver disease. Hepatol. (Baltimore, Md) 2020. https://doi.org/10.1002/hep.31173.
Chen F, Esmaili S, Rogers GB et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. Hepatology 2020; 71: 1213-1227.
Kim D, Kim WR. Nonobese fatty liver disease. Clin. Gastroenterol. Hepatol. 2017; 15: 474-485.
Niriella MA, Kasturiratne A, Pathmeswaran A et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hepat. Int. 2019; 13: 314-322.
Feldman A, Denkmayr L, Strasser M et al. Liver-related mortality and morbidity of lean NAFLD is higher compared to overweight and obese NAFLD patients. J. Hepatol. 2017; 66: S149.
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J. Hepatol. 2017; 67: 862-873.
Li C, Guo P, Okekunle AP et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients. J. Gastroenterol. Hepatol. 2019; 34: 256-262.
Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS ONE 2015; 10: e0140908.
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84.
Shi Y, Wang Q, Sun Y et al. The prevalence of lean/nonobese nonalcoholic fatty liver disease: a systematic review and meta-analysis. J. Clin. Gastroenterol. 2019; 54: 378-387.
Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology 2016; 64: 19-22.
Nishioji K, Mochizuki N, Kobayashi M et al. The impact of PNPLA3 rs738409 genetic polymorphism and weight gain ≥ 10 kg after age 20 on non-alcoholic fatty liver disease in non-obese Japanese individuals. PLoS ONE 2015; 10: e0140427.
Wong VWS, Chan WK, Chitturi S et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017 part 1: definition, risk factors and assessment. J. Gastroenterol. Hepatol. 2018; 33: 70-85.
GBD 2015 Obesity Collaborators, Afshin A, Reitsma MB, Sur P et al. Health effects of overweight and obesity in 195 countries over 25 years. New England J. Med. 2017; 377: 13-27.
Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 2017; 15: 11-20.
Honarvar B, Lankarani KB, Keshani P, Rafiee T. Dietary determinants of non-alcoholic fatty liver disease in lean and non-lean adult patients: a population-based study in Shiraz, Southern Iran. Hepat. Mon. 2017; 17: e44962.
Lee C, Kim J, Jung Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Cell 2019; 8: 1259.
Tobari M, Hashimoto E. Characteristic features of nonalcoholic fatty liver disease in Japan with a focus on the roles of age, sex and body mass index. Gut Liver 2020. https://doi.org/10.5009/gnl19236.
Alam S, Fahim SM, Chowdhury MAB. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open 2018; 2: 39-46.
Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 2012; 47: 586-595.
Bertolotti M, Lonardo A, Mussi C et al. Nonalcoholic fatty liver disease and aging: epidemiology to management. World J. Gastroenterol. 2014; 20: 14185-14204.
Nishioji K, Sumida Y, Kamaguchi M et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J. Gastroenterol. 2015; 50: 95-108.
Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J. Gastroenterol. 2003; 38: 954-961.
Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J. Gastroenterol. Hepatol. 2012; 27: 1555-1560.
Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin. Diab: a publication of the American Diabetes Association 2019; 37: 65-72.
Dela Cruz AC, Bugianesi E, George J et al. Characteristics and long-term prognosis of lean patients with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: S909-S.